Would you like timely critical insights that enhance your businesses in a competitive marketplace? We’ve engaged 87,000 physicians worldwide in our active community of validated and active treaters that includes valuable Medical Key Opinion Leaders and ThoughtLeaders.
Continue reading
It can be a lengthy and challenging process to identify the right healthcare ThoughtLeaders to serve as advocates for pharmaceutical brands. At MDOutlook, we make it easy to identify, engage and deploy Healthcare ThoughtLeaders who can drive value for companies. Our precision engagement platform connects lifesciences marketing teams to more than 14,000 ThoughtLeaders and 120,000+ healthcare professionals across every disease state.
Companies in this dynamic and competitive market can gain an edge when using accurate, real-time information to guide timely, strategic decisions. MDOutlook offers clients immediate access to verified and active Healthcare ThoughtLeaders, from oncology to rare diseases, who can support the development and marketing of new treatments.
With Healthcare ThoughtLeaders available in more than 60 cancer types, spanning 120 countries, and operating at all geographic levels — global, national, regional and local – pharma brands can unlock access to exactly the right treaters at the right stages of a product’s lifecycle to maximize adoption rates and profitability.
By using an HCP engagement platform, such as MDOutlook’s Lumineer, companies can build more effective strategies to increase sales. By identifying, mapping and engaging healthcare ThoughtLeaders with real-time data and business intelligence, pharma brands can design treatment marketing plans and HCP engagement strategies that resonate widely with the decision makers who affect institutions and formularies.
Here are a few of the most exciting features on our HCP engagement platform:
Precision Intelligence
Lumineer provides resources that help lifesciences brands identify the most qualified Healthcare ThoughtLeaders in targeted markets. With accurate, real-time data about professional experience, published works, and institutional connections, companies can begin to map out webs of influence to enhance treatment success. Lumineer is a robust information resource for pharma teams looking to hire and engage TLs for specific goals.
Extensive HCP Profiles
Lumineer’s intuitive dashboard provides companies direct access to MDOutlook’s ThoughtLeader Attribute Dial that meshes public and proprietary data to build extensive profiles of Healthcare ThoughtLeaders, whom users can then rank based on specific search criteria. A strong engagement platform will provide opportunities far beyond the top-50 TL lists and make it easy to intelligently prepare for high-value meetings.
Visual Dashboard
Our business intelligence dashboard provides a snapshot of market, business and HCP data in an easily digestible, visual format. Infographics provide easy access to important data about Healthcare ThoughtLeaders, including visualization of peer nomination maps, that help brands deepen their queries and identify the right HCPs for specific project goals.
Peer Nomination Networks
Through our unique peer nomination process, brands can receive trusted information about target HCPs through a variety of tangible and intangible rankings. When qualified clinicians nominate their peers within a specific disease area based on their participation in clinical research, published work and speaking engagements, brands can begin to understand how their advocacy can drive awareness and adoption of new treatments. These networks might make visible a clear, institutional leader, or perhaps a rising industry star, who has amassed credibility in a disease area and can assist in the development and marketing of treatments. One of our clients used Lumineer to uncover early adopters for specific cancer treatment when testing treatment volumes and finding high-writers of prescriptions.
Peer-To-Peer Programs
Once a company has mapped out HCPs, it can engage and recruit influential Healthcare ThoughtLeaders through educational programs. With 77% of HCPs now using digital channels primarily for personal learning and development, brands have a unique opportunity to build educational resources that incentivize HCPs to engage. with KOLs they trust. MDOutlook offers tools for companies to design and launch meaningful live conversations that educate HCPs about treatments fulfilling unmet market needs. Brands can then disseminate information created by KOLs during these touchpoints to further engage HCPs in target markets.
Lumineer Can Drive Meaningful Results
As pharmaceutical companies navigate a challenging marketplace where time and accuracy are of the essence, a robust HCP engagement platform like Lumineer can accelerate company goals and drive differentiation.
By connecting brands to thorough and timely insights complemented with extensive searching tools, brands can begin to strategically map out the HealthCare ThoughtLeaders who will be able to drive meaningful brand value and profitability.
To round off these efforts, pharma brands use MDOutlook’s DocPulse for up-to-date research and insights, Activeer for unique peer-to-peer programs and activations, and Consultative Insights for brand-specific analyses and advanced modeling.
Learn how Lumineer can help your brand get the most out of your HCP engagement strategy by intelligently mapping the landscape of HCPs. Contact us to schedule a free demo today!
Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages.
Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares insights.
Tracking your impact post-conference matters
Having a data announcement at a conference (such as ESMO) can speak volumes. However, following a client survey of 147 US oncologists, we tracked impact from the messaging activity and observed little difference with attention captured at conferences when compared to post-conference. This pattern reflects what is normally seen in the market.
About half (n=75) of the US oncologists who did not attend ESMO rate their awareness of the news from ESMO as relatively high.
Nearly two-thirds of academic non-attendees rate their awareness of ESMO results as high or very high and by comparison, still almost half of US community oncologists rated their level of awareness on a similar basis. Attending conferences is still seen as valuable for new data announcements, but in an age of instant communications, attendance is not required to stay up to date.
Learning from colleagues
In another study, we helped a client track the impact of a hematology announcement by assessing the source and reach of results learned among oncologists from different nationalities who did not attend the conference. A higher proportion of (71%) EU oncologists who did not attend the conference learned of the results from a colleague who did attend compared to US oncologists (56%).
Biopharmaceutical companies need reliable partners with winning expertise and experience knowing what it takes to master these trends. In a highly competitive space where hyper-targeting is essential, MDOutlook provides clients with the right mix of agile assets, value solutions, and professional customer access to drive successful precision engagement with your most relevant customers in oncology, hematology, and rare diseases.
Meet us at ASH
We deliver value to our clients by engaging the right professional customers to inform the clients’ business decisions and commercialization strategies of their assets in the right way throughout the product cycle.
Let’s take your next step together by arranging at the ASH annual meeting (7th to 10th December) in Orlando or arranging a more convenient date / time to scope out your future success!
For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.
Oncology conferences such as American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) are critically important industry resources that create valuable opportunities to conduct oncology market research so that more life-saving cancer treatments can reach the patients who need them.
The European Society for Medical Oncology, or ESMO, has amassed clout in recent years as its influence has grown and the size and diversity of its audience widened. As the world’s premier congress in medical oncology, ESMO’s importance has grown as its global platform has widened. In 2021, ESMO attracted nearly 33,000 participants from 155 countries and nearly 3,000 submitted abstracts, surpassing the nearly 30,000 registrants from 137 countries it attracted before the pandemic in 2019.
There’s also been a noticeable rise in popularity and importance of highly targeted disease-focused conferences, such as European Hematology Association (EHA), the International Association for the Study of Lung Cancer (IASLC) and The International Conference on Malignant Lymphoma (ICML), as well as breakout meetings under the auspices of ASCO and ESMO that focus on one cancer.
From general to targeted, oncology’s scientific conferences present a platform to disseminate new disease state data, hold high-value meetings with healthcare providers (HCPs), and exchange oncology market research with a global audience.
Biopharmaceutical companies who work with reliable agency partners can more effectively leverage high-value conferences such as ESMO and ASCO to increase sales of new and existing treatments. MDOutlook has valuable industry expertise and knows what it takes to master oncology industry trends. Our HCP engagement platform provides clients with granular oncology market research about the catalysts driving industry momentum.
In a highly competitive space where hyper-targeting the right HCPs is essential to differentiation, MDOutlook provides clients with a cauldron of oncology market research and engagement tools that include:
When used together, brands can build powerful HCP engagement strategies targeted at the clinicians who are responsible for prescribing decisions in oncology, hematology, and rare disease. This way, when sales teams show up for a headline event such as ESMO, they’re coming prepared with a list of target HCPs, intelligent talking points, survey questions, and other educational touchpoints that engage relevant clinicians in meaningful discussions.
When an HCP engagement platform is robust, it can provide search filters and precision insights that give brands critical market data about the way the market, notably clinicians, are perceiving a treatment.
With one client, we interviewed oncologists in a rare disease area who were all specifically attending ICML in Lugano, Switzerland to measure the impact of its new data announcements. The challenge was intensified by the fact that the timing of the conference was directly after EHA and the client needed to engage oncologists based in the US who were attending a highly European-focused meeting.
MDOutlook was able to leverage its engagement platform to rapidly identify, reach and survey target clinicians. This resulted in quickly delivered, hyper-targeted oncology market research that guided our client’s treatment announcements.
Whether you are assessing the impact of a data announcement, trying to understand the disease state for which you are developing, or have another project in mind that requires hyper-targeting of your professional customers, MDOutlook’s oncology market research can help.
When brands access the sophisticated targeting of MDOutlook’s Lumineer platform, they leverage critical oncology market research to hyper-target oncologists who are critical to treatment development and marketing strategies. Companies can search by geography, event attendance, research, institutional affiliation, influence and more to answer focused questions about treatments and market dynamics.
MDOutlook enables client success through proprietary software assets and access to the world’s largest verified community of more than 140,000 treaters and experts in oncology, hematology, and rare disease. Lumineer combines self-reported characteristics with external data then applies machine-learning and artificial intelligence to deliver rich insights that support marketing and development strategies.
Learn more about how Lumineer can hyper-target HCPs in the disease areas you care about and help you design complex engagement strategies with the clinicians who can drive market adoption and boost treatment profitability. Contact us to schedule a free demo today.
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019.
The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where patients had previously undergone treatment with one of the 2nd generation antiandrogens and docetaxel.
Impact of announcement
There was a general perception among prostate cancer ThoughtLeaders at ESMO 2019 that Cabazitaxel could become a new standard in mCRPC post-docetaxel and 2nd generation antiandrogen. Cabazitaxel is already widely available in many countries aiding the anticipated changes in treatment practices and guidelines. Contrary to current standard practices, switching to novel hormonal agents has been shown to be much less effective.
Our work with prostate cancer treating clinicians
Our work with prostate cancer treating clinicians (see slide for details of our track record and robust prostate cancer treating community) suggests that there will be some significant resistance to change treatment paradigms by cancer treaters especially amongst urologists. In past studies, cancer treaters were less likely to use chemotherapy due to perceived side effects and more likely to use novel hormonal agents despite the lack of supporting evidence especially in older patients. What is your take on the new data presented at ESMO 2019? Let’s set-up a call to further discuss.
Beyond prostate cancer, we offer rich experience, expertise and robust treaters and experts access in all solid, hematological & rare cancers.
Meet us
Let’s take your next step together by arranging a meeting at your offices to scope out your future success!
For further discussion or to arrange a meeting, please contact [email protected] or call +1.404.496.4136.
MDOutlook empowers confident business decisions with valuable precision insights and actionable intelligence.
At the recent 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at the congress to gain a richer understanding of their practices in a number of different tumor-areas and to collect real-world evidence (RWE). The interactive workshops proved highly successful and delivered a better understanding of the current practices of radiation-oncologists across indications to create value across functions (marketing, market access, and medical affairs).
We address client challenges across the product lifecycle and different business functions. During the conference season, for example, we are particularly busy helping clients gain valuable insight into their data presentations as well as measuring impact as can be seen from post-ASCO articles (clinical impact of ASCO presentations covering integration-of-new-treatment-regimens-in-CLL; novel-targeted-agents-for-MNSCLC and what-will-happen-in-NMCRPC and MHSPC.) published in partnership with OBR earlier this Summer.
We specialize in:
Meet us
Let’s take your next step together by arranging a meeting at your offices to scope out your future success!
For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.
ImmunoOncology (IO) expands the treatment possibilities and provides substantial clinical benefit, especially in patients who had little to no effective treatment options less than a decade ago. IO features prominently at the 2019 annual European Society for Medical Oncology (ESMO) annual congress in Barcelona where agenda items will cover topics such as the current biomarkers in immunotherapy (e.g. PD-L1) and understanding the emerging role of I/O in gastro enterological (GI) cancers.
While IO therapies are among the most promising drugs they are associated with high cost.
Value of medicines number one concern for oncologists.
Financial impact and affordability of medicines are the number one concern for oncologists reported in MDOutlook’s 2019 Leadership research in ImmunoOncology. Oncologists were asked to choose their top three areas (from fourteen attributes) for corporate leaders to improve most in the next three years.
The sentiment was especially pronounced with US based oncologists where almost half (47%) worry about the financial impact of oncology medications on the healthcare system and patients. In Europe, similar concerns are also shared by a large group of oncologists (37%), and equally viewed as the most concerning aspects moving forward. This coincides with the debate on the value of medicines picking up speed on both continents, and in Europe, more regulators and payors are working together on joint HTA assessments and cross-border purchasing (e.g. BeNeLuxA initiative).
While financial considerations do not materially influence oncologists treatment decisions, the rising cost of medications is an ever-present worry. The surveyed oncologists fear insufficient value may have a toxic financial effect on the overall healthcare system.
Earlier and accelerated access
Oncologists in our research would like to see better and earlier access to innovative treatments for their patients. Financial support mechanisms such as patient support programs play an important role in making a difference for patients. Aligning your market access programs and strategies with the needs of healthcare professionals will further help to alleviate widely held concerns of “financial toxicity”. Communications and marketing functions also need to improve their messages and materials to communicate enhanced and differentiated value (see our analysis above) for all stakeholders in the healthcare system.
Meet us at ESMO
With IO presentations featuring prominently at major conferences (such as ESMO), it is vital to be in tune with treaters and experts views and have access to timely precision intelligence and actionable recommendations in order to adapt your engagement with your professional audience. Our international teams are uniquely positioned to provide you with vital ingredients of experience, expertise, treaters & ThougthLeader engagement and agile solutions to empower client confidence when guiding commercial strategies.
With wide ranging solutions such as ONCpulse™, we can rapidly access verified and highly relevant oncologists and experts specific to any solid, liquid or rare cancer to capture their views through our large international community.
Let’s take your next step together by meeting at the ESMO annual meeting (September 27 – October 1st) in Barcelona or arranging a more convenient date / time to scope out your future success!
For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.
In today’s climate, the imperative for new products or brands to achieve their full potential quickly has never been greater. Key to achieving success is measuring and communicating progress, both internally and externally. Tracking your product is an iterative process of measuring, managing and monitoring key performance indicators (KPIs) for the market, your product, your competitors.
At MDOutlook, we empower clients with timely precision insights and give confidence in navigating brands successfully in unforgiving markets.
Improve your commercial strategy
Drawing from our large and validated database of over 120,000 treaters and ThoughtLeaders (TL) in oncology, we identified for one of our clients the root cause of their lack of market share and performed an analysis of 8 key EU markets. We were able to deliver profound customer insights that changed our client’s strategy.
Our client, an international pharmaceutical company, was faced with a dilemma in that one of their brands was not performing well against KPIs, and their market share was stagnant shortly after launch. While there were KPI assessments in place, the client lacked deep customer insights. By exploring and triangulating relevant aspects of KPI, ATU, key account analysis and ThoughtLeader research we gained superior insights (such as measuring message impact; assessing brand uptake; understanding prescribing drivers and barriers; tracking switching patterns and competitive activity over time) that aided our client to change their brand strategy, and their market share tripled in 18 months!
Our KPI measurement approach contributed to our client generating north of €100m in additional sales by continuing to hone their strategies and tactics at both European and country levels!
KPI excellence delivering results!
Utilizing our services, we enable clients to gain a deep understanding of each brand’s unique value proposition. We take a 360-degrees approach (triangulating the right specific and impact information) to understand the barriers and enablers that impact your business.
A critical foundation to our success in tracking KPIs is developing base measurements and planning for uninterrupted performance monitoring to inform confident commercialization decisions.
A critical foundation to our success in tracking KPIs is developing base measurements and planning for uninterrupted performance monitoring to inform confident commercialization decisions.
Engaging our core agile and adaptive services helps MDOutlook deliver actionable KPI precision intelligence and directly actionable recommendations.
Let´s discuss how we can contribute to your brand’s success through our excellence in KPI measurement. Contact us today at [email protected] or call at +1 404.496.4136 to take the next step.
We will be at the ESMO annual meeting (27 September – 1 October) in Barcelona and look forward to welcoming you there.
Increasingly, biopharmaceutical companies recognize the importance and value of identifying and engaging ‘rising stars’ since they are typically younger, tech-engaged, offer novel perspectives, future ThoughtLeaders and a window to tomorrow’s healthcare market.
Similarly, clients are increasingly using MDOutlook precision intelligence to identify the most relevant rising star ThoughtLeaders (TL; also known as KOLs, External Experts, or Therapy Experts) for their interactions and commercialization activities.
Whilst the top TLs are well recognized, identifying rising star TLs is much more challenging. We lighten this process for our clients by providing unparalleled access to over 12,000 validated TLs and well over 120,000 qualified treaters in oncology.
Rising stars are evolving experts in their therapy area and scientific field, committed to enhancing clinical research and building their scientific footprint and reputation. Our easy-to-use database with advanced analytics and data visualization, identifies rising stars and generates short lists for client use on a scheduled basis.
By utilizing machine learning and artificial intelligence to track physician activity in multiple research domains on dozens of data points, and across our defined TL hierarchy, rising stars typically populate Tiers 2 and 3 within our definition. Additionally, this is also the level where peer nominations – the voice of their community – can provide an early indication of upward momentum.
We regularly work with clients at and around medical congresses enriching and enhancing their TL engagement strategies at these pivotal events. In a recent project, we identified rising stars in acute myeloid leukemia (AML) to support our client’s commercialization activities and targeting of this valuable group.
Our insights conclude that rising star TLs are an imperative to any biopharmaceutical company integrated TL strategy since they represent:
Whether you are engaging with ThoughtLeaders digitally, personally or on the phone, we support you on your knowledge journey. We provide expert insights and ThoughtLeader identification that will make your advisory councils, expert calls, congresses, and virtual engagements a success! At MDOutlook, we help clients to leverage ThoughtLeaders throughout the commercialization lifecycle of a compound and maximize both opportunities and revenues.
We are passionate about our precision intelligence offering and provide you with rapid and actionable answers to all your business questions. All our solutions are scalable to fit your needs & budgets, including integration with legacy systems.
We will be at the ESMO annual meeting (27 September – 1 October) in Barcelona and look forward to welcoming you there.
For further discussion on this or other topics, and to arrange a meeting at your convenience, please contact [email protected] or call +1 404.496.4136.
After every major conference, MDOutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them.
Even with these CLL presentations being on the last day of ASCO, the awareness and enthusiasm for the use of Venetoclax + Obinutuzumab, Acalabrutinib + Obinutuzumab, and the CD19-targeted CAR-T cell product Lisocabtagene Maraleucel does not seem to be dampened. In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and how these regimens will be integrated into clinical practice. As can be seen from the data excerpt, there is good reason to assume that the new regimens will be making quite an impact throughout the treatment process.
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site.
Last week, we published our post-ASCO OncoPolls on early advanced prostate cancer (nmCRPC and mHSPC) and on novel targeted agents in mNSCLC.
If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.
